Eric Lefkofsky is the co-founder and chair of Tempus Labs whose goal is to increase treatment options for patients living with cancer. Consequently, Tempus Labs liaises with healthcare professionals, scientists, and researchers to ensure data that can improve the effectiveness of patient care and treatment is readily available for use by physicians and clinicians. Having access to a searchable database empowers physicians and assists them in the analysis of molecular and clinical information so cancer treatment can be individualized on a patient-by-patient basis. In one of his published articles, Lefkofsky stated, “Healthcare, as an industry, is ripe for technological disruption. The potential for positive impact, particularly in the area of cancer care, is both enormous and imminent.” Tempus Labs is “disrupting” healthcare by revolutionizing cancer care through genomic sequencing.
As a leader in biotechnology, Tempus Labs is a successful startup. Established in 2015, Tempus Labs has received more than $200 million in funding from contributors like New Enterprise Associates, Revolution Growth, Kinship Trust Company, and T. Rowe Price Associates, a fund adviser. A recent infusion in investment dollars boosted the valuation of Tempus Labs to $1.1 billion. With this milestone, Tempus Labs earned the title “unicorn,” a term that defines a startup with a valuation of more than $1 billion. This accomplishment is rare since the majority of startups fail within 4-5 years.
Along with his wife, Liz, Eric has extended his community support and outreach through the Lefkofsky Family Foundation (LFF), a charitable foundation dedicated to philanthropy. The goal of LFF mirrors the purpose of Tempus Labs, namely, “enhancing the quality of human life” which it does particularly in education, human rights, medicine, arts, and culture. In the area of education, LFF partners with the Academy of Urban School Leadership, the University of Chicago’s Urban Education Institute, the Chicago Public Schools, After School Matters, and Teach for America, to develop tomorrow’s leaders today.
Learn More: www.lightbank.com/team/eric-lefkofsky
Cancer is a disease that the medical system struggles to solve. Every year, millions of people suffer the adverse effects of cancer. Cancer Treatment Centers of America is a company that helps people who are affected by this disease.The company is increasing sales each year. As a result, numerous jobs are available for people who are interested. One of the best aspects of Cancer Treatment Centers of America is that the company positively impacts the lives of other people.
One of the most popular jobs with the company involves patient care. Some people who have cancer die from the disease. The families of the victims need help with the grieving process. There is a huge need for qualified workers in this field.Another primary need for families is financial planning. It is financially difficult to deal with the death of a family member. Few people make preparations for this process.Cancer Treatment Centers of America focuses on hiring people who have experience in the medical field. The company also wants to hire workers who want to help others.
The company plans to open additional locations throughout the United States in the coming years. The company needs workers who have a background in real estate. Purchasing commercial property is a lengthy process that requires experience.
Cancer Treatment Centers of America is also hiring workers for the financial planning department. As the company grows, the leaders want to manage the finances appropriately. Hiring additional workers will ensure the company can help as many patients as possible.
Mitt Romney recently announced that last summer he underwent surgery to treat a slow-growing tumor found in his prostate. Dr. David Samadi, Chairman of Urology at Lenox Hill Hospital published an article to clarify for readers the implications of getting diagnosed with prostate cancer. According to Dr. David Samadi, when the cancer is still localized within the prostate, so it hasn’t metastasized and spread to other parts of the body, the prognosis for the patient is excellent, depending on the treatment option they choose.
Men with localized prostate cancer can have their prostates removed by surgery or they can undergo radiation treatment. They must choose. Radiation therapy uses targeted radiation to attempt to kill all the cancer cells. Dr. David Samadi always advises these patients to remove their prostate. Because all the cancer cells are in the prostate, they are entirely removed along with the prostate. The success rate for the patients who have their prostates removed by surgery is close to 100%. According to studies, men who receive the radiation therapy have twice the death rate. And, according to the studies, they are one-and-a-half times more likely sooner than the men who choose the surgery.
Dr. David Samadi mentions another possible consequence of receiving radiation therapy that is not known by many people. Radiation is a known carcinogen. That is, radiation causes cancer. And this is just as true of the radiation therapy used to treat cancer. Every exposure to radiation raises the patient’s risk of developing other tumors. Men receiving radiation therapy for prostate cancer have an increased risk of cancers of the bladder and rectum, and even of developing more prostate cancer in the future. Also, it’s difficult to perform prostate surgery after radiation therapy. If the man receives radiation instead of surgery and later discovers the cancer has spread to other parts of the body, the chance of surviving for five or more years drops to 30%.
In 2007, Dr. David Samadi went to work at Mt Sinai School of Medicine. He became their Chief of Robotics and Minimally Invasive Surgery. by 2012 he earned $6.7 million, the highest-paid doctor in New York City. A year later, he moved to Lenox Hill Hospital where he is also the Chief of Robotic Surgery. He belongs to the American Medical Association and the American Urological Association. He attracts attention to his practice by appearing in the media more than most doctors.
Two brilliant oncologists from the Roswell Park Cancer Insitute managed to develop an online medical journal that can be reviewed by the members of the scientific community. Dr. Mikhail Blagosklonny and Andrei V. Gudkov are the proponents of the online medical journal entitled Oncotarget, and they are currently serving as the website’s editors in chief. Their extensive knowledge about cancer has given them the idea to create an online medical journal, and they wanted to post all information that they know online so that other scientists can see it as well. They are also encouraging other oncologists worldwide to submit their discoveries about cancer to broaden the knowledge of the scientific community about the disease. Established in 2010, Oncotarget managed to reach millions of people around the world, and the online medical journal is now releasing articles twice a week. Aside from cancer, the online medical journal is also incorporating articles that tackle about fatal and incurable diseases, to help scientists discover a possible treatment or cure in the future. Check the journal at SCImago Journal & Country Rank.
Despite the advancement of technology and medicine, cancer remains an incurable disease. However, oncologists are still optimistic that the cure for the disease can be discovered one day, especially now that an online medical journal like Oncotarget exists. Today, people are trying to cope with treatment that has adverse side effects like chemotherapy, but in the future, the cure for cancer can be introduced in the form of a pill, and it can be dispatched all throughout the globe for hospitals to use. Scientists are sharing this information through Oncotarget, and it has been a habit for them to speculate and share their insights as to how cancer can be eradicated using the present technology that we have.
Learn more: https://www.ncbi.nlm.nih.gov/pmc/journals/1558/
Oncotarget continues to become the leading resource for scientists around the world who are trying to look for scholarly articles when dealing with cancer and other fatal diseases. Dr. Mikhail Blagosklonny and Andrei V. Gudkov are also encouraging other oncologists around the world to contribute some knowledge that will help other oncologists on the other side of the planet deal with cancer. Download output styles at Endnote.com